Management of Coagulopathy in Postpartum Hemorrhage.

abstract：:Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are altepl...

journal_title：Seminars in thrombosis and hemostasis

authors： Campbell J,Hilleman D

更新日期：2010-07-01 00:00:00

abstract：:Of all the coagulation factor deficiencies, only deficiency of factor XIII (FXIII) and fibrinogen are associated with pregnancy loss. FXIII deficiency and a complete or partial deficiency of fibrinogen are associated with bleeding since childhood, impaired wound repair, and recurrent spontaneous abortions. Both FXIII ...

journal_title：Seminars in thrombosis and hemostasis

authors： Inbal A,Muszbek L

更新日期：2003-04-01 00:00:00

abstract：:Prophylactic treatment from ages 2 to 18 years could prevent the development of hemophilic arthropathy if the concentration of the patient's deficient factor is kept from falling below 1% of normal. Early treatment is of paramount importance because the immature skeleton is very sensitive to the complications of hemop...

journal_title：Seminars in thrombosis and hemostasis

authors： Rodriguez-Merchan EC

更新日期：2003-02-01 00:00:00

abstract：:Protein S is a vitamin K-dependent plasma glycoprotein circulating in plasma at a concentration of around 350 nM. Approximately 60% of protein S in human plasma is bound to the complement regulatory protein C4b-binding protein (C4BP) in a high-affinity, high-molecular-weight complex. Protein S in plasma has multiple a...

journal_title：Seminars in thrombosis and hemostasis

authors： Dahlbäck B

更新日期：2018-03-01 00:00:00

abstract：:Arterial and venous thromboses are major contributors to coagulation-associated morbidity and mortality. Greater understanding of mechanisms leading to thrombus formation and stability is expected to lead to improved treatment strategies. Factor XIII (FXIII) is a transglutaminase found in plasma and platelets. During ...

journal_title：Seminars in thrombosis and hemostasis

authors： Byrnes JR,Wolberg AS

更新日期：2016-06-01 00:00:00

abstract：:In the Netherlands, specialized care for patients with a bleeding disorder, including hemophilia, von Willebrand disease (VWD), and allied disorders, is concentrated in 13 Hemophilia Treatment Centers. The Dutch Hemophilia Treaters Society, the Dutch Hemophilia Nurses' Society, and the Netherlands Hemophilia Patients ...

journal_title：Seminars in thrombosis and hemostasis

authors： de Wee EM,Leebeek FW,Eikenboom JC

更新日期：2011-07-01 00:00:00

abstract：:The long-term success rate of coronary angioplasty is only 50 to 70% due to restenosis. The pathophysiologic mechanism of this event is mainly mediated by smooth muscle cell proliferation. To some extent, it can be inhibited by heparin. The introduction of LMWHs allows for prophylaxis against restenosis on an outpatie...

journal_title：Seminars in thrombosis and hemostasis

authors： Lojewski B,Bacher P,Iqbal O,Walenga JM,Hoppensteadt DA,Leya F,Fareed J

更新日期：1993-01-01 00:00:00

abstract：:Factor (F) VIII is a large gene located near the terminus of the long arm of the X chromosome. It contains 26 exons that code for a signal peptide and a 2332 amino acid polypeptide with three different types of domains, namely A1-A2-B-A3-C1-C2. The A domains are homologous with each other and those of ceruloplasmin; s...

journal_title：Seminars in thrombosis and hemostasis

authors： Thompson AR

更新日期：2003-02-01 00:00:00

abstract：:Plasma levels of total homocysteine (tHcy), a possible risk factor for vascular disease, are generally lower in women than in men and lower in premenopausal women than in postmenopausal women. This article reviews studies that have investigated associations of hyperhomocysteinemia with risk of vascular disease among w...

journal_title：Seminars in thrombosis and hemostasis

authors： Verhoef P

更新日期：2000-01-01 00:00:00

abstract：:Thrombotic diseases, as potentially induced by blood clots or vascular embolization, frequently occur with high rates of mortalities worldwide. Current drug thrombolysis, a primary clinical therapy, may increase fatal risk of hemorrhage when thrombolysis agents become systemically distributed. Given current thrombolys...

journal_title：Seminars in thrombosis and hemostasis

authors： Qu S,Ding X

更新日期：2020-07-01 00:00:00

abstract：:Anticoagulant therapy reduces deaths and disability in patients with or at risk of both arterial and venous thromboembolism. Highly effective antithrombotic therapies now exist that reduce the risk of both arterial thrombosis and venous thrombosis. Anticoagulant strategies include platelet inhibition, using a variety ...

journal_title：Seminars in thrombosis and hemostasis

authors： Goy J,Crowther M

更新日期：2012-10-01 00:00:00

abstract：:A new in vitro system for the detection of platelet dysfunction, PFA-100, has been developed. It provides a quantitative measure of platelet function in anticoagulated whole blood. The system comprises a microprocessor-controlled instrument and a disposable test cartridge containing a biologically active membrane. The...

journal_title：Seminars in thrombosis and hemostasis

authors： Kundu SK,Heilmann EJ,Sio R,Garcia C,Davidson RM,Ostgaard RA

更新日期：1995-01-01 00:00:00

abstract：:Several studies have suggested that patients with non-O blood group have an increased risk of both venous and arterial thromboembolic events. On the contrary, the role of ABO blood group on the risk of bleeding complications remains unclear. Thus, we performed a meta-analysis of the literature with the aim of assessin...

journal_title：Seminars in thrombosis and hemostasis

authors： Dentali F,Sironi AP,Ageno W,Bonfanti C,Crestani S,Frattini F,Steidl L,Franchini M

更新日期：2013-02-01 00:00:00

abstract：:We have explored the molecular basis of the clinical therapeutic effect of factor VIIa in hemophilia A using empirical reconstituted in vitro thrombin generation models. Tissue factor acts as a receptor and activator of preexistent but virtually inactive two-chain plasma factor VIIa. However, most of the factor VII ci...

journal_title：Seminars in thrombosis and hemostasis

authors： van't Veer C,Mann KG

更新日期：2000-01-01 00:00:00

abstract：:Platelets have classically been considered crucial effector cells in hemostasis, but now are increasingly recognized as players during inflammatory responses in innate and adaptive immunity. Platelets can recognize and kill invading pathogens, and, upon stimulation, also release a wide array of mediators that modify i...

journal_title：Seminars in thrombosis and hemostasis

authors： Kim SJ,Davis RP,Jenne CN

更新日期：2018-03-01 00:00:00

abstract：:Pregnancy is associated with a significant procoagulant shift in the hemostatic system balance as well as other metabolic changes. Pregnancy can thereby provoke manifestation of otherwise dormant disorders of hemostasis (e.g., thrombophilia), or even cause new, pregnancy-specific disorders (e.g., HELLP syndrome). Appl...

journal_title：Seminars in thrombosis and hemostasis

authors： Ataullakhanov FI,Koltsova EM,Balandina AN,Serebriyskiy II,Vuimo TA,Panteleev MA

更新日期：2016-10-01 00:00:00

abstract：:Molecular genetic analysis of families with hemophilia and other heritable bleeding disorders is a frequently requested laboratory investigation. In the United Kingdom, laboratories undertaking genetic testing must participate in a recognized external quality assessment scheme for formal accreditation. The UK National...

journal_title：Seminars in thrombosis and hemostasis

authors： Perry DJ,Cumming T,Goodeve A,Hill M,Jennings I,Kitchen S,Walker I

更新日期：2014-03-01 00:00:00

abstract：:The risk for arteriosclerosis and thrombosis of patients with severe hyperhomocysteinemia is reduced by homocysteine-lowering therapy. Whether this is the case in patients with mild hyperhomocysteinemia remains to be proved. Another challenge for researchers is to establish a satisfying pathological mechanism of the v...

journal_title：Seminars in thrombosis and hemostasis

authors： Blom HJ

更新日期：2000-01-01 00:00:00

abstract：:Congenital amegakaryocytic thrombocytopenia (CAMT, MIM #604498) is a rare inherited bone marrow failure syndrome presenting as isolated hypomegakaryocytic thrombocytopenia at birth without other characteristic physical anomalies. Most of the patients develop a severe aplastic anemia and trilineage cytopenia during the...

journal_title：Seminars in thrombosis and hemostasis

authors： Ballmaier M,Germeshausen M

更新日期：2011-09-01 00:00:00

abstract：:Systolic heart failure is a common syndrome whose incidence is expected to increase. Several treatment modalities, such as beta-blockers and angiotensin-converting enzyme inhibitors, improve survival. Whether antithrombotic treatment is effective remains to be elucidated, although observations suggest a prothrombotic ...

journal_title：Seminars in thrombosis and hemostasis

authors： de Peuter OR,Kok WE,Torp-Pedersen C,Büller HR,Kamphuisen PW

更新日期：2009-07-01 00:00:00

abstract：:Physiologic regulation of fibrinolysis plays an important role in the control of hypercoagulable states and thrombogenesis. Both the hereditary and acquired conditions leading to fibrinolytic deficit result in thrombotic complications leading to arterial and venous occlusive disorders. Several changes in physiologic s...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Hoppensteadt DA,Jeske WP,Ahmad S,Bick RL

更新日期：1999-01-01 00:00:00

abstract：:The molecular basis for the hereditary type I protein S (PS) deficiency was investigated. DNA sequence analysis of 12 patients with PS deficiency in Japan identified four point mutations and three of them were novel. Nonsense mutations found in two unrelated patients resulted in termination of the PS polypeptide chain...

journal_title：Seminars in thrombosis and hemostasis

authors： Iwaki T,Mastushita T,Kobayashi T,Yamamoto Y,Nomura Y,Kagami K,Nakayama T,Sugiura I,Kojima T,Takamatsu J,Kanayama N,Saito H

更新日期：2001-01-01 00:00:00

abstract：:Severe factor XI (FXI) deficiency is an injury-related bleeding disorder common in Ashkenazi Jews and rare worldwide. In the past two decades, more than 180 mutations in the FXI gene have been reported in patients with FXI deficiency, five of which show a founder effect (Cys38Arg, Gln88Stop, Cys128Stop, Glu117stop, an...

journal_title：Seminars in thrombosis and hemostasis

authors： Duga S,Salomon O

更新日期：2009-06-01 00:00:00

abstract：:Thrombotic events are uncommon disorders in childhood but increasingly recognized due to the progress made in the understanding of the hemostasis system and the importance of thromboembolic disorders in children. Multiple clinical underlying conditions and prothrombotic disorders contribute to the development of throm...

journal_title：Seminars in thrombosis and hemostasis

authors： Tormene D,Gavasso S,Rossetto V,Simioni P

更新日期：2006-10-01 00:00:00

abstract：:The PFA-100 (platelet function analyzer) is a relatively new tool for the investigation of primary hemostasis. This article reviews the history of the PFA-100 and details its clinical utility in several settings. The PFA-100 was first introduced to us in 1995 in an issue of Seminars in Thrombosis And Hemostasis, which...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ

更新日期：2008-11-01 00:00:00

abstract：:Vatreptacog alfa is a genetically engineered variant of recombinant factor VIIa (rFVIIa) containing three amino acid changes. Aspartic acid, valine, and glutamine residues replace valine, glutamic acid, and methionine at positions 158, 296, and 298, respectively. These substitutions result in considerable enhancement ...

journal_title：Seminars in thrombosis and hemostasis

authors： Persson E,Olsen OH,Bjørn SE,Ezban M

更新日期：2012-04-01 00:00:00

abstract：:The functional operation of the cell surface pro-u-PA and plasminogen activating system has previously been shown to depend on the assembly of u-PA receptors, plasminogen binding sites, and their respective ligands at the focal adhesions of cell extensions. We now show that additional factors operate that affect the p...

journal_title：Seminars in thrombosis and hemostasis

authors： Stephens RW,Pöllänen J,Tapiovaara H,Woodrow G,Vaheri A

更新日期：1991-07-01 00:00:00

abstract：:It has been demonstrated that the surface of large VLDL Sf 100-400 can bind both prothrombin and Factor X(Xa) and that on VLDL Factor Xa can convert prothrombin to thrombin, which degrades apo B and apo E. It has been reported also that the VLDL kinetically supports the conversion of prothrombin to thrombin. The bindi...

journal_title：Seminars in thrombosis and hemostasis

authors： Bradley WA,Gianturco SH

更新日期：1988-07-01 00:00:00

abstract：:Platelet-type von Willebrand disease (PT-VWD) and type 2B von Willebrand disease (2B-VWD) are rare bleeding disorders characterized by increased ristocetin-induced platelet aggregation (RIPA) at low concentrations of ristocetin. Diagnosis of either condition is not easy and the differential diagnosis between the two e...

journal_title：Seminars in thrombosis and hemostasis

authors： Woods AI,Sanchez-Luceros A,Bermejo E,Paiva J,Alberto MF,Grosso SH,Kempfer AC,Lazzari MA

更新日期：2014-03-01 00:00:00

abstract：:Platelets possess three P2 receptors: two (P2Y (1) and P2Y (12)) are receptors for adenosine diphosphate (ADP), and one (P2X1) is a receptor for adenosine triphosphate (ATP). The P2Y (1) receptor, which is coupled to Gq and phospholipase C-beta, is responsible for mobilization of ionized calcium from internal stores a...

journal_title：Seminars in thrombosis and hemostasis

authors： Cattaneo M

更新日期：2005-04-01 00:00:00